Page last updated: 2024-08-26

sr141716 and Parkinson Disease, Secondary

sr141716 has been researched along with Parkinson Disease, Secondary in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brotchie, JM; Crossman, AR; Maneuf, YP	1

Other Studies

1 other study(ies) available for sr141716 and Parkinson Disease, Secondary

Article	Year
The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Experimental neurology, 1997, Volume: 148, Issue:1 Topics: Animals; Basal Ganglia; Benzazepines; Benzoxazines; Dopamine Agonists; gamma-Aminobutyric Acid; Locomotion; Male; Morpholines; Naphthalenes; Nerve Tissue Proteins; Parkinson Disease, Secondary; Piperidines; Pyrazoles; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Drug; Reserpine; Rimonabant	1997

Article

Year

The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.

Experimental neurology, 1997, Volume: 148, Issue:1

Topics: Animals; Basal Ganglia; Benzazepines; Benzoxazines; Dopamine Agonists; gamma-Aminobutyric Acid; Locomotion; Male; Morpholines; Naphthalenes; Nerve Tissue Proteins; Parkinson Disease, Secondary; Piperidines; Pyrazoles; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Drug; Reserpine; Rimonabant

1997